Skip to main content
Top

2011 | OriginalPaper | Hoofdstuk

10. Immuuntherapie van kanker

Auteurs : Prof. Dr. S. Osanto, Dr. W. H. J. Kruit

Gepubliceerd in: Oncologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het idee dat de natuurlijke afweerkrachten van het lichaam bescherming bieden tegen kanker, is al zeer oud. Aan het begin van de vorige eeuw veronderstelde Paul Ehrlich dat vooral de cellulaire immuniteit, vertegenwoordigd door leukocyten, beschermt tegen tumorgroei. Later werd zelfs gepostuleerd dat een van de belangrijkste functies van de cellulaire immuniteit bewaking tegen tumorgroei is. Thans weten we dat deze theorie in ieder geval geldt voor virus-geïnduceerde tumoren, zoals met epstein-barr-virus (EBV-)infectie samenhangende tumoren, en baarmoederhalskanker, veroorzaakt door humaan papillomavirus. Vooral bij virus-geïnduceerde tumoren zijn de veranderingen in de tumorcellen groot genoeg om ze herkenbaar te maken als lichaamsvreemde elementen voor het specifieke immuunsysteem.
Literatuur
go back to reference Bruggen P van der, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science 1991;254:1643–7.CrossRefPubMed Bruggen P van der, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science 1991;254:1643–7.CrossRefPubMed
go back to reference Dudley ME. Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4.CrossRefPubMedPubMedCentral Dudley ME. Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4.CrossRefPubMedPubMedCentral
go back to reference Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679–80.CrossRefPubMed Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679–80.CrossRefPubMed
go back to reference Hodi FS, Mohm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Scie USA 2003;100:4712–7.CrossRef Hodi FS, Mohm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Scie USA 2003;100:4712–7.CrossRef
go back to reference Hsu FJ, Clemens BC, Czerwinski D, et al. Tumor-specific idiotype in the treatment of patients with B-cell lymphoma long-term results of a clinical trial. Blood 1997;89:3129–35.PubMed Hsu FJ, Clemens BC, Czerwinski D, et al. Tumor-specific idiotype in the treatment of patients with B-cell lymphoma long-term results of a clinical trial. Blood 1997;89:3129–35.PubMed
go back to reference Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126–9.CrossRefPubMedPubMedCentral Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126–9.CrossRefPubMedPubMedCentral
go back to reference Nestlé FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.CrossRefPubMed Nestlé FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.CrossRefPubMed
go back to reference Osanto S. Vaccine trials for the clinician: Prospects for tumor antigens. Oncologist 1997;2:284–99.PubMed Osanto S. Vaccine trials for the clinician: Prospects for tumor antigens. Oncologist 1997;2:284–99.PubMed
go back to reference Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systematic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92.CrossRefPubMed Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systematic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92.CrossRefPubMed
go back to reference Rosenberg SA, Yanelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159–66.CrossRefPubMed Rosenberg SA, Yanelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159–66.CrossRefPubMed
go back to reference Vries IJ de, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumorspecific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779–87.CrossRefPubMed Vries IJ de, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumorspecific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779–87.CrossRefPubMed
Metagegevens
Titel
Immuuntherapie van kanker
Auteurs
Prof. Dr. S. Osanto
Dr. W. H. J. Kruit
Copyright
2011
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8476-1_10